RuDo Logo
Talk to an adviser

SBI Healthcare Opportunities Fund Direct Plan Growth

Direct plan · Growth · Pharma and Healthcare · SBI Funds Management Private Limited

₹623.72

-₹4.35 (-0.69%) on the day

NAV on 16 Nov 2026. Mutual funds publish one NAV a day, after the market closes.

Near its 52-week high (-0.7%)

What stands out

This fund +25.09%BSE Healthcare +18.43%14 Nov 2025 to 16 Nov 2026 (BSE Healthcare to 13 Nov 2026)
Return1 day1 week1 month3 months6 monthsThis year1 year3 years5 years10 years
This fund-0.69%-0.15%+10.65%+3.55%+17.10%+28.65%+25.09%+24.88%+20.26%+16.24%
In US dollarssame as UAE dirhams------+17.79%+19.81%+14.73%+12.52%
BSE Healthcareto 13 Nov 2026-0.24%+2.36%+8.43%+3.63%+14.60%+20.74%+18.70%+22.33%+15.89%+13.24%
Average of pharma and healthcare funds--+9.34%+3.28%+13.66%+23.11%+20.54%+22.13%+16.56%-
Rank among them--2/197/185/184/186/172/121/10-

Returns from the plan's own NAVs to 16 Nov 2026. 3, 5 and 10 years are a yearly rate. Rank 1 is the best return; green is the top half, red the bottom half. Past performance does not indicate future returns.

If you had invested

You invest

₹6.00 L

60 months from Dec 2021

Worth today

₹10.77 L

+79.4%

₹10,000 at the start of every month, valued at the NAV of 16 Nov 2026. Before tax. Past performance does not indicate future returns.

Calendar years ahead of BSE Healthcare8 of 10

Where it ranks

among 19 pharma and healthcare funds, Direct plans

1 year

6 of 17

Second quarter

3 years

2 of 12

Top quarter

5 years

1 of 10

Top quarter

Lowest cost

7 of 18

Second quarter

Best over 3 years3 yr a yearCost
1HDFC Pharma and Healthcare Fund+30.9%1.03%
2SBI Healthcare Opportunities Fund this fund+24.9%1.01%
3Mirae Asset Healthcare Fund+23.9%0.62%
4UTI Healthcare Fund+23.6%1.34%
5LIC MF Healthcare Fund+21.9%1.37%

Every fund in the category computed from its own NAV the same way, to 16 Nov 2026. All Pharma and Healthcare funds ›

Fund details

52-week range of the NAV

-0.7% from the high of 12 Nov 2026

₹462.87₹628.12

Fund size

₹5,870 Cr

Yearly cost (expense ratio)

1.01%

Regular plan 1.99%: ₹980 more a year on ₹1 lakh

Exit load

0.50% on or before 15D, Nil after 15D

Minimum SIP

₹500

Lump sum from ₹5,000

Risk level

Very High

Benchmark

BSE Healthcare

Fund manager

Tanmaya Desai

Launched

1 Jan 2013

Risk at a glance

Ups and downs (volatility), 3 years

14.4%

a year; BSE Healthcare 16.0%

Worst fall since launch

-30.5%

Oct 2015 to Mar 2020; back by Jun 2020

Worst calendar year

-12.9%

2016; best 2020 +67.7%

Months that ended up

69%

of the last 36 months

Against other pharma and healthcare funds, last 3 years (worst fall: 5 years)

Volatility

✓ 14.4%

Steadier than peers · average 15.9%

1 of 13

Worst fall

= -17.4%

In line with peers · average -18.2%

3 of 10

Sharpe ratio

✓ 1.31

More return for the risk · average 1.08

2 of 12

Yearly cost

= 1.01%

About average · average 1.10%

7 of 18

More measures ›

Sharpe ratio, 3 years

1.31

Return above the CRISIL Overnight Index per unit of volatility

Sortino ratio, 3 years

2.75

The same, counting only falls

Alpha vs BSE Healthcare

+4.22%

Yearly return beyond what its beta explains

Beta vs BSE Healthcare

0.92

Moves this much when the index moves 1%

Share of the index's rises

101%

In months the index rose

Share of the index's falls

82%

In months the index fell; lower is better

Over the last 3 years, from the fund's NAVs against the BSE Healthcare.

Rolling returns

Every 3-year holding period, month by month, as a yearly rate

Made money

81%

of periods

Beat BSE Healthcare

95%

of periods

Worst

-7.9%

a year, to Oct 2018

Best

+36.2%

a year, to Jan 2016

This fund (solid) and BSE Healthcare (dashed): 131 periods from month-end NAVs. Past performance does not indicate future returns.

Compare rolling returns with other funds, in ₹, $ or AED ›

What it holds

34 holdings, as of Aug 2026
  1. 1Sun Pharmaceutical Industries Ltd12.33%
  2. 2Divi'S Laboratories Ltd8.17%
  3. 3AMI Organics Ltd4.91%
  4. 4Apollo Hospitals Enterprises Ltd4.91%
  5. 5Torrent Pharmaceuticals Ltd4.72%
  6. 6Cipla Ltd4.67%
  7. 7Max Healthcare Institute Ltd4.31%
  8. 8Cash, TREPS and repo4.11%
  9. 9Laurus Labs Ltd3.96%
  10. 10Aurobindo Pharma Ltd3.90%
Show all 34 ›
  1. 11Aster Dm Healthcare Ltd3.52%
  2. 12Gland Pharma Ltd2.99%
  3. 13Anthem Biosciences Ltd2.90%
  4. 14Sudeep Pharma Ltd2.84%
  5. 15Fortis Healthcare Ltd2.82%
  6. 16Biocon Ltd2.67%
  7. 17Jupiter Life Line Hospitals Ltd2.55%
  8. 18SAI Life Sciences Ltd2.52%
  9. 19Concord Biotech Ltd2.40%
  10. 20Aether Industries Ltd2.33%
  11. 21Poly Medicure Ltd1.94%
  12. 22Global Health Ltd1.91%
  13. 23Ajanta Pharma Ltd1.86%
  14. 24Suven Pharmaceuticals Ltd1.73%
  15. 25Krishna Institute of Medical Sciences Ltd1.73%
  16. 26Mankind Pharma Ltd1.67%
  17. 27Dr. Lal Pathlabs Ltd1.47%
  18. 28Healthcare Global Enterprises Ltd1.27%
  19. 29Syngene International Ltd1.24%
  20. 30Nephrocare Health Services Ltd1.18%
  21. 31Rainbow Children'S Medicare Ltd0.73%
  22. 32Abbott India Ltd0.35%
  23. 33Gufic Biosciences Ltd0.29%
  24. 34364 DAY T-BILL 19.11.260.05%

Top 10: 56.0% of the fund. Check overlap with another fund ›

By company size

  • Large cap32.3%
  • Mid cap25.7%
  • Small cap37.5%
  • Other (cash, foreign, debt)4.5%

Shares by sector

  • Healthcare94.5%
  • Materials2.3%
P/E of holdings
70.2
Turnover a year
36%

Year by year

Year2026 so far202520242023202220212020201920182017
This fund+28.6%-2.5%+43.7%+39.7%-5.0%+21.5%+67.7%+0.5%-8.8%+3.3%
BSE Healthcare+20.7%-3.3%+43.5%+37.0%-12.1%+20.9%+61.4%-3.5%-5.9%+0.5%
Average of pharma and healthcare funds+23.5%-2.7%+43.0%+38.0%-8.6%+22.0%+68.9%+5.3%--
From the plan's own NAVs. The current year is to date.

SIP returns of pharma and healthcare funds · Fund returns in dollars · All pharma and healthcare funds · Fund screener

About SBI Healthcare Opportunities Fund Direct Plan Growth

SBI Healthcare Opportunities Fund Direct Plan Growth is a Sector Specific - Pharma equity fund from SBI Funds Management Private Limited, launched on 1 Jan 2013. Its benchmark is the BSE Healthcare Index. The expense ratio is 1.01% a year. It manages ₹5,870 crore. The NAV was ₹623.72 on 16 Nov 2026. Over 10 years it returned 16.24% a year in rupees and 12.52% a year in US dollars and UAE dirhams, as the rupee fell 3.31% a year against the dollar.

Questions about SBI Healthcare Opportunities Fund

What is the NAV of SBI Healthcare Opportunities Fund Direct Growth?

The NAV of SBI Healthcare Opportunities Fund Direct Growth was ₹623.72 on 16 Nov 2026. Mutual fund NAVs are published once a day, after markets close.

What are the returns of SBI Healthcare Opportunities Fund Direct Growth?

SBI Healthcare Opportunities Fund Direct Growth returned 25.1% over 1 year, 24.9% a year over 3 years, 20.3% a year over 5 years and 16.2% a year over 10 years, to 16 Nov 2026, worked out from its own daily NAV. It returned more than the BSE Healthcare Index in 9 of 10 calendar years since 2017.

What has SBI Healthcare Opportunities Fund returned in US dollars and UAE dirhams?

In US dollars it returned 17.8% over 1 year, 19.8% a year over 3 years, 14.7% a year over 5 years and 12.5% a year over 10 years. The rupee fell 3.3% a year against the dollar over 10 years, which accounts for the gap from the rupee return. The UAE dirham is pegged to the dollar, so returns in dirhams are the same.

What is the expense ratio of SBI Healthcare Opportunities Fund Direct Growth?

1.01% a year. It is taken from the fund's assets every day, so the NAV and every return shown are already after this cost.

Can NRIs in the UAE invest in SBI Healthcare Opportunities Fund?

NRIs can generally invest once KYC is complete, paying from an NRE or NRO account. SBI Mutual Fund accepts investors living in the US or Canada only on conditions, per its scheme documents checked on 15 Nov 2026. Rules change, so confirm with the fund house.

How are SBI Healthcare Opportunities Fund gains taxed for NRIs?

India taxes gains on equity funds at 20% on units held 12 months or less, and at 12.5% on gains above ₹1.25 lakh a year on units held longer, plus cess and any surcharge. For NRIs the tax is deducted when units are redeemed. The UAE has no personal income tax, and the India UAE tax treaty may apply, so confirm your position with a tax adviser.

Rolling returns in dollars shows every period, not just the latest.

Compare every pharma and healthcare fund on returns, volatility, worst fall and cost.

Investing from the UAE. NRIs can generally invest once KYC is complete, paying from an NRE or NRO account. Some fund houses restrict residents of the US and Canada. India taxes equity fund gains at 20% on units held 12 months or less and 12.5% above ₹1.25 lakh a year after that, plus cess and any surcharge, deducted when an NRI redeems. The UAE has no personal income tax and the India UAE treaty may apply, so confirm your position with a tax adviser.

Data from RuDo Wealth fund analytics, NAV as of 16 Nov 2026; benchmark as named by SBI Funds Management Private Limited. India: RuDo Wealth Investment Advisory, SEBI Registered Investment Adviser, registration INA000019503. UAE: RuDo Digital Wealth, FSRA Financial Services Permission 220155, Category 3C (Retail), ADGM. General information, not a recommendation to buy or sell this fund. Past performance does not indicate future returns.